There are 2789 resources available
520MO - Using patient-reported outcomes (PROs) in dose-finding oncology trials (DFOT): Results from a global stakeholder survey and the National Cancer Research Institute (NCRI) Consumer Forum
Presenter: Julia Lai-Kwon
Session: Mini oral session - Developmental therapeutics
Resources:
Abstract
Slides
Webcast
343MO - Clinical features and DNA methylation patterns in long- and short-term survivors of WHO grade II-III glioma
Presenter: Maximilian Mair
Session: Mini oral session - CNS tumours
Resources:
Abstract
Slides
Webcast
344MO - Experience of GEINO (Spanish cooperative group for research in neuro-oncology) oncologists in the management of adult medulloblastoma
Presenter: Maria Vieito Villar
Session: Mini oral session - CNS tumours
Resources:
Abstract
Slides
Webcast
1039MO - CheckMate 204: 3-year outcomes of treatment with combination nivolumab (NIVO) plus ipilimumab (IPI) for patients (pts) with active melanoma brain metastases (MBM)
Presenter: Kim Margolin
Session: Mini oral session - Melanoma and other skin tumours
Resources:
Abstract
Slides
Webcast
515MO - A phase I trial of durvalumab (Durv) in combination with olaparib (Ola) and capivasertib (Cap) in patients (pts) with advanced or metastatic cancers (Ca) (MEDIPAC)
Presenter: Joline Lim
Session: Mini oral session - Developmental therapeutics
Resources:
Abstract
Slides
Webcast
516MO - Phase I/II study of eprenetapopt (APR-246) in combination with pembrolizumab in patients with solid tumor malignancies
Presenter: Haeseong Park
Session: Mini oral session - Developmental therapeutics
Resources:
Abstract
Slides
Webcast
517MO - Phase I study of the porcupine (PORCN) inhibitor RXC004 in patients with advanced solid tumours
Presenter: Natalie Cook
Session: Mini oral session - Developmental therapeutics
Resources:
Abstract
Slides
Webcast
LBA13 - Predictive impact of biomarkers on pCR and survival after de-escalated neoadjuvant T-DM1 with or without endocrine therapy (ET) vs. trastuzumab+ET in HER2+/HR+ early breast cancer: WSG ADAPT TP trial
Presenter: Nadia Harbeck
Session: Mini oral session - Breast cancer, early stage
Resources:
Abstract
Slides
Webcast
Introduction by the chair
Presenter: Edward Garon
Session: Patients with metastatic progression on or shortly after durvalumab consolidation for stage III NSCLC should be treated
Resources:
Slides
Webcast
Consistent with regimens appropriate for initial treatment of metastatic disease
Presenter: Federico Cappuzzo
Session: Patients with metastatic progression on or shortly after durvalumab consolidation for stage III NSCLC should be treated
Resources:
Slides
Webcast